Filtered By:
Drug: Kaletra
Countries: Iran Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 124 results found since Jan 2013.
Changes in PD-1- and CTLA-4-bearing blood lymphocytes in ICU COVID-19 patients treated with Favipiravir/Kaletra or Dexamethasone/Remdesivir: a pilot study
This study evaluated the frequency of whole blood lymphocytes expressing PD-1 and CTLA-4 in COVID-19 patients upon admission to the intensive care unit (ICU) (i.e., severe) or infection ward (i.e., moderate) and after 7 days of antiviral therapy. COVID-19 patients were treated with either favipiravir or Kaletra (FK group, 11 severe and 11 moderate) or dexamethasone plus remdesivir (DR group, 7 severe and 10 moderate) for 7 days in a pilot study. Eight healthy control subjects were also enrolled. The frequency of PD-1+ and CTLA-4+ lymphocytes in whole blood was evaluated by flow cytometry. Patients on DR therapy had shorter...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Esmaeil Mortaz Hamidreza Jamaati Neda K Dezfuli Hakime Sheikhzade Seyed MohammadReza Hashemian Neda Dalil Roofchayee Frazaneh Dastan Payam Tabarsi Gert Folkerts Johan Garssen Sharon Mumby Ian M Adcock Source Type: research
